Can I reuse my CE file for Saudi Arabia (SFDA)?

Written by Niko Mangold

In short: Yes, to a large degree. SFDA's technical framework closely mirrors EU MDR, so much of a CE technical file transfers to an MDMA application. Since 9 September 2026, a CE certificate issued after Notified Body assessment can also support the SFDA's reliance pathway, which reduces the documentation required and brings review of a complete application to 35–60 working days. Self-declared devices do not qualify, and software and AI-enabled devices can be excluded at the SFDA's discretion.

Why the overlap is unusually good here

Saudi Arabia's medical device regulator, SFDA, built its Medical Device Marketing Authorization (MDMA) framework with deliberate structural similarity to EU MDR — closer, in practice, than the relationship between MDR and FDA's submission logic. Device classification, the general safety and performance requirement structure, and the expected technical documentation sections in an SFDA submission map closely enough to an MDR technical file that a well-built CE dossier is genuinely the strongest starting point for an MDMA application, not just a helpful reference.

What SFDA requires, and what your CE mark is worth

Since 1 January 2022, SFDA has required a complete technical file for every MDMA application under its MDS-REQ 1 requirements, which closed an older route that accepted CE or FDA determinations more directly. Since 9 September 2026, guidance MDS-G30 has added a reliance pathway: an approval from a recognised authority in the EU, the US, the UK, Canada, Australia, or Japan reduces the documentation you submit and shortens the review. The device must be identical to the approved one, and approvals based on equivalence to a predicate, such as a US 510(k), do not qualify. The SFDA still makes its own decision, so draw the file from your CE dossier and confirm with your Authorised Representative which documents the reliance route lets you leave out.

What still needs local adaptation

Even with strong structural overlap, an MDMA submission needs its own cover documentation, needs to be submitted through your appointed in-country Authorised Representative — itself an establishment licensed by SFDA — and needs any labeling or language requirements specific to the Saudi market addressed directly rather than assumed to carry over from your EU documentation. Re-confirm your device classification under SFDA's rules too: it usually mirrors MDR, but that isn't guaranteed. Treat the CE file as your evidence base and starting structure, not a document you resubmit unchanged — plan for adaptation, not just translation.

Where next: SFDA Medical Device Registration (MDMA) · Do I need an in-country representative in Saudi Arabia?

Talk to us about your SFDA registration strategy. Book an expert conversation →